pRL-null载体

pRL-null载体

收藏
  • ¥800
  • ZYbscience
  • 中国/美国
  • ZY2271
  • 2025年07月15日
    avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 技术资料
    • 保存条件

      -20℃低温保存

    • 保质期

      三年

    • 英文名

      pRL-null

    • 库存

      20

    • 供应商

      泽叶生物

    载体基本信息

    出品公司: ZYbscience
    载体名称: pRL-null
    质粒类型: 海肾荧光素酶报告载体;哺乳动物载体
    高拷贝/低拷贝: 高拷贝
    克隆方法: 限制性内切酶,多克隆位点
    启动子: CMV
    载体大小: 3320 bp
    5' 测序引物及序列: CMV Forward: CGCAAATGGGCGGTAGGCGTG
    3' 测序引物及序列: --
    载体标签: --
    载体抗性: 氨苄青霉素
    筛选标记: --
    克隆菌株: TOP10等常规菌株
    宿主细胞(系): 哺乳动物细胞
    备注: --
    产品目录号: ZY2271
    稳定性: 瞬表达 或 稳表达
    组成型/诱导型: 组成型
    病毒/非病毒: 非病毒

    载体质粒图谱和多克隆位点信息

    pRL-null载体图谱



    pRL-null 多克隆位点

    pRL-null 载体特征

    载体简介

    The pRL-null Vector(a,b) (Figure 1) is intended for use in constructing a control
    reporter vector that may be used in combination with any experimental reporter vector
    to cotransfect mammalian cells. All of Promega’s pRL Reporter Vectors contain a
    cDNA(b) (Rluc) encoding Renilla luciferase, which was originally cloned from the
    marine organism Renilla reniformis (sea pansy; 1). As described below, the Renilla
    luciferase cDNA contained within the pRL Vectors has been modified slightly to
    provide greater utility.
    The pRL-null Vector contains no enhancer or promoter elements. Rather, it contains
    a multiple cloning region upstream of Rluc to allow for the cloning of any desired regulatory
    element(s) to drive expression of Renilla luciferase. Renilla luciferase is a
    36kDa monomeric protein that does not require post-translational modification for
    activity (2). Therefore, like firefly luciferase, the enzyme may function as a genetic
    reporter immediately following translation. For information about the use of this plasmid
    in conjunction with a reporter vector containing the firefly luciferase gene, refer
    to the Dual-Luciferase Reporter Assay System(c,d) Technical Manual (#TM040).
    The pRL Vectors are isolated from a dam–/dcm– E. coli K host strain, allowing
    digestion with restriction enzymes that are sensitive to dam and dcm methylation.
    The GenBank/EMBL Accession Number for the pRL-null Vector is AF025844.
    
    Features of the pRL-null Vector
    
    A. Multiple Cloning Region
    The pRL-null Vector contains a multiple cloning region positioned immediately
    upstream of the chimeric intron and Renilla luciferase reporter gene (Figure 2).
    To aid in devising cloning strategies, Table 1 summarizes the types of DNA ends
    generated from restriction endonuclease digestion within the multiple cloning
    region as well as the compatibility of those ends with the ends of DNA fragments
    generated by heterologous restriction enzymes.
    
    B. Chimeric Intron
    Downstream of the multiple cloning region of the pRL-null Vector is a chimeric
    intron comprised of the 5′-donor splice site from the first intron of the human
    β-globin gene, and the branch and 3′-acceptor splice site from an intron preceding
    an immunoglobulin gene heavy chain variable region (3). The sequences of
    the donor and acceptor splice sites, along with the branchpoint site, have been
    modified to match the consensus sequences for optimal splicing (4).
    Transfection studies have demonstrated that the presence of an intron flanking a
    cDNA insert frequently increases the level of gene expression (5–8). In the
    pRL-null Vector the intron is positioned 5′ to Rluc to minimize the utilization of
    cryptic 5′-donor splice sites that may reside within the reporter gene sequence (9).
    
    C. T7 Promoter
    A T7 promoter is located downstream of the chimeric intron and immediately
    precedes the Rluc reporter gene. This T7 promoter can be used to synthesize
    RNA transcripts in vitro using T7 RNA Polymerase (Cat.# P2075). T7 RNA
    Polymerase can also be used to synthesize active Renilla luciferase in a cell-free
    coupled eukaryotic in vitro transcription/translation reaction (e.g., Promega’s
    TNT Reticulocyte Lysate(c,e,f,g) [Cat.# L4610], TNT T7 Coupled Wheat Germ
    Extract(c,e,f,g) [Cat.# L4140] or TNT T7 Quick Coupled Transcription/Translation
    (c,e,f,g,h) [Cat.# L1170] Systems).
    
    D. Renilla Luciferase Reporter Gene (Rluc)
    The Renilla luciferase cDNA inserted into all of the pRL Vectors is derived from
    the anthozoan coelentrate Renilla reniformis (1) but contains nucleotide changes
    that were engineered during the construction of the individual vectors. The following
    bases were altered in the pRL-null Vector: base 539 (T→C), to eliminate
    an internal Bgl II site; base 1082 (T→C), to eliminate an internal BamH I site;
    base 1115 (C→T), to eliminate internal Nar I, Kas I, Ban I and Acy I sites. These
    nucleotide substitutions do not alter the amino acid sequence of the encoded
    Renilla luciferase reporter enzyme.
    
    E. SV40 Late Polyadenylation Signal
    Polyadenylation signals cause the termination of transcription by RNA polymerase
    II and signal the addition of approximately 200–250 adenosine residues
    to the 3′-end of the RNA transcript (10). Polyadenylation has been shown to
    enhance RNA stability and translation (11,12). The late SV40 polyadenylation
    signal, which is extremely efficient and has been shown to increase the steadystate
    level of RNA approximately 5-fold over the early SV40 polyadenylation signal
    (13), has been positioned 3′ to the Rluc gene in the pRL-null Vector to
    increase the level of Renilla luciferase expression.
    
    IV. Transfection of Mammalian Cells with the pRL-null Vector
    
    The pRL-null Vector, once it has been modified to contain appropriate genetic regulatory
    domains, may be used in combination with any experimental reporter vector to
    cotransfect mammalian cells. However, it is important to realize that trans effects
    between promoters on cotransfected plasmids can potentially affect reporter gene
    expression (14). Primarily this is of concern when either the control or experimental
    reporter vector, or both, contain very strong promoter/enhancer elements. The
    occurrence and magnitude of such effects will depend on several factors: i) the combination
    and activities of the genetic regulatory elements present on the cotransfected
    vectors; ii) the relative ratio of experimental vector to control vector introduced
    into the cells; and iii) the cell type transfected.
    To help ensure independent genetic expression between experimental and control
    reporter genes, preliminary cotransfection experiments should be performed to optimize
    both the amount of vector DNA and the ratio of the coreporter vectors added to
    the transfection mixture. Similar to the firefly luciferase assay, the Renilla luciferase
    assay is extremely sensitive, providing accurate measurement of ≤10 femtograms of
    Renilla luciferase, with linearity over seven orders of enzyme concentration.
    Therefore, it is possible to use relatively small quantities of the pRL-null Vector to
    provide low-level, constitutive coexpression of Renilla luciferase control activity.
    The pRL-null Vector, once genetic regulatory domains have been added, can be
    used for both transient and stable expression of Renilla luciferase. For stable expression,
    the pRL-null Vector must be cotransfected with an expression vector containing
    a selectable gene in mammalian cells. Transfection of DNA into mammalian cells
    may be mediated by cationic lipids (15,16), calcium phosphate (17,18), DEAEDextran
    (19–21), polybrene-DMSO (22,23), or electroporation (24,25).
    Transfection systems based on cationic lipid compounds (TransFast Reagent(i),
    Tfx Reagents(j) and Transfectam Reagent(k)), calcium phosphate and DEAEDextran
    are available from Promega. For more information and a protocol for the
    Transfectam Reagent, please request the Transfectam Reagent Technical Bulletin
    (#TB116) and for the TransFast Reagent, please request the TransFast
    Transfection Reagent Technical Bulletin (#TB260). Protocols for the use of the
    Tfx Reagents can be found in the Tfx-10, Tfx-20 and Tfx-50 Reagents for
    the Transfection of Eukaryotic Cells Technical Bulletin (#TB216). For transfection procedures
    using calcium phosphate or DEAE-Dextran, please request the ProFection
    Mammalian Transfection Systems Technical Manual (#TM012).
    

    载体序列

       1  AGATCTCGAG CTCTAAGCTT CACATATGCA TGCACTAGTG GCGCCTGTCG
    
      51  ACGCGTAGAA TTCACCCGGG TACTGCAGAA GTTGGTCGTG AGGCACTGGG
    
     101  CAGGTAAGTA TCAAGGTTAC AAGACAGGTT TAAGGAGACC AATAGAAACT
    
     151  GGGCTTGTCG AGACAGAGAA GACTCTTGCG TTTCTGATAG GCACCTATTG
    
     201  GTCTTACTGA CATCCACTTT GCCTTTCTCT CCACAGGTGT CCACTCCCAG
    
     251  TTCAATTACA GCTCTTAAGG CTAGAGTACT TAATACGACT CACTATAGGC
    
     301  TAGCCACCAT GACTTCGAAA GTTTATGATC CAGAACAAAG GAAACGGATG
    
     351  ATAACTGGTC CGCAGTGGTG GGCCAGATGT AAACAAATGA ATGTTCTTGA
    
     401  TTCATTTATT AATTATTATG ATTCAGAAAA ACATGCAGAA AATGCTGTTA
    
     451  TTTTTTTACA TGGTAACGCG GCCTCTTCTT ATTTATGGCG ACATGTTGTG
    
     501  CCACATATTG AGCCAGTAGC GCGGTGTATT ATACCAGACC TTATTGGTAT
    
     551  GGGCAAATCA GGCAAATCTG GTAATGGTTC TTATAGGTTA CTTGATCATT
    
     601  ACAAATATCT TACTGCATGG TTTGAACTTC TTAATTTACC AAAGAAGATC
    
     651  ATTTTTGTCG GCCATGATTG GGGTGCTTGT TTGGCATTTC ATTATAGCTA
    
     701  TGAGCATCAA GATAAGATCA AAGCAATAGT TCACGCTGAA AGTGTAGTAG
    
     751  ATGTGATTGA ATCATGGGAT GAATGGCCTG ATATTGAAGA AGATATTGCG
    
     801  TTGATCAAAT CTGAAGAAGG AGAAAAAATG GTTTTGGAGA ATAACTTCTT
    
     851  CGTGGAAACC ATGTTGCCAT CAAAAATCAT GAGAAAGTTA GAACCAGAAG
    
     901  AATTTGCAGC ATATCTTGAA CCATTCAAAG AGAAAGGTGA AGTTCGTCGT
    
     951  CCAACATTAT CATGGCCTCG TGAAATCCCG TTAGTAAAAG GTGGTAAACC
    
    1001  TGACGTTGTA CAAATTGTTA GGAATTATAA TGCTTATCTA CGTGCAAGTG
    
    1051  ATGATTTACC AAAAATGTTT ATTGAATCGG ACCCAGGATT CTTTTCCAAT
    
    1101  GCTATTGTTG AAGGTGCCAA GAAGTTTCCT AATACTGAAT TTGTCAAAGT
    
    1151  AAAAGGTCTT CATTTTTCGC AAGAAGATGC ACCTGATGAA ATGGGAAAAT
    
    1201  ATATCAAATC GTTCGTTGAG CGAGTTCTCA AAAATGAACA ATAATTCTAG
    
    1251  AGCGGCCGCT TCGAGCAGAC ATGATAAGAT ACATTGATGA GTTTGGACAA
    
    1301  ACCACAACTA GAATGCAGTG AAAAAAATGC TTTATTTGTG AAATTTGTGA
    
    1351  TGCTATTGCT TTATTTGTAA CCATTATAAG CTGCAATAAA CAAGTTAACA
    
    1401  ACAACAATTG CATTCATTTT ATGTTTCAGG TTCAGGGGGA GGTGTGGGAG
    
    1451  GTTTTTTAAA GCAAGTAAAA CCTCTACAAA TGTGGTAAAA TCGATAAGGA
    
    1501  TCCAGGTGGC ACTTTTCGGG GAAATGTGCG CGGAACCCCT ATTTGTTTAT
    
    1551  TTTTCTAAAT ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCCTGA
    
    1601  TAAATGCTTC AATAATATTG AAAAAGGAAG AGTATGAGTA TTCAACATTT
    
    1651  CCGTGTCGCC CTTATTCCCT TTTTTGCGGC ATTTTGCCTT CCTGTTTTTG
    
    1701  CTCACCCAGA AACGCTGGTG AAAGTAAAAG ATGCTGAAGA TCAGTTGGGT
    
    1751  GCACGAGTGG GTTACATCGA ACTGGATCTC AACAGCGGTA AGATCCTTGA
    
    1801  GAGTTTTCGC CCCGAAGAAC GTTTTCCAAT GATGAGCACT TTTAAAGTTC
    
    1851  TGCTATGTGG CGCGGTATTA TCCCGTATTG ACGCCGGGCA AGAGCAACTC
    
    1901  GGTCGCCGCA TACACTATTC TCAGAATGAC TTGGTTGAGT ACTCACCAGT
    
    1951  CACAGAAAAG CATCTTACGG ATGGCATGAC AGTAAGAGAA TTATGCAGTG
    
    2001  CTGCCATAAC CATGAGTGAT AACACTGCGG CCAACTTACT TCTGACAACG
    
    2051  ATCGGAGGAC CGAAGGAGCT AACCGCTTTT TTGCACAACA TGGGGGATCA
    
    2101  TGTAACTCGC CTTGATCGTT GGGAACCGGA GCTGAATGAA GCCATACCAA
    
    2151  ACGACGAGCG TGACACCACG ATGCCTGTAG CAATGGCAAC AACGTTGCGC
    
    2201  AAACTATTAA CTGGCGAACT ACTTACTCTA GCTTCCCGGC AACAATTAAT
    
    2251  AGACTGGATG GAGGCGGATA AAGTTGCAGG ACCACTTCTG CGCTCGGCCC
    
    2301  TTCCGGCTGG CTGGTTTATT GCTGATAAAT CTGGAGCCGG TGAGCGTGGG
    
    2351  TCTCGCGGTA TCATTGCAGC ACTGGGGCCA GATGGTAAGC CCTCCCGTAT
    
    2401  CGTAGTTATC TACACGACGG GGAGTCAGGC AACTATGGAT GAACGAAATA
    
    2451  GACAGATCGC TGAGATAGGT GCCTCACTGA TTAAGCATTG GTAACTGTCA
    
    2501  GACCAAGTTT ACTCATATAT ACTTTAGATT GATTTAAAAC TTCATTTTTA
    
    2551  ATTTAAAAGG ATCTAGGTGA AGATCCTTTT TGATAATCTC ATGACCAAAA
    
    2601  TCCCTTAACG TGAGTTTTCG TTCCACTGAG CGTCAGACCC CGTAGAAAAG
    
    2651  ATCAAAGGAT CTTCTTGAGA TCCTTTTTTT CTGCGCGTAA TCTGCTGCTT
    
    2701  GCAAACAAAA AAACCACCGC TACCAGCGGT GGTTTGTTTG CCGGATCAAG
    
    2751  AGCTACCAAC TCTTTTTCCG AAGGTAACTG GCTTCAGCAG AGCGCAGATA
    
    2801  CCAAATACTG TTCTTCTAGT GTAGCCGTAG TTAGGCCACC ACTTCAAGAA
    
    2851  CTCTGTAGCA CCGCCTACAT ACCTCGCTCT GCTAATCCTG TTACCAGTGG
    
    2901  CTGCTGCCAG TGGCGATAAG TCGTGTCTTA CCGGGTTGGA CTCAAGACGA
    
    2951  TAGTTACCGG ATAAGGCGCA GCGGTCGGGC TGAACGGGGG GTTCGTGCAC
    
    3001  ACAGCCCAGC TTGGAGCGAA CGACCTACAC CGAACTGAGA TACCTACAGC
    
    3051  GTGAGCTATG AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA GGCGGACAGG
    
    3101  TATCCGGTAA GCGGCAGGGT CGGAACAGGA GAGCGCACGA GGGAGCTTCC
    
    3151  AGGGGGAAAC GCCTGGTATC TTTATAGTCC TGTCGGGTTT CGCCACCTCT
    
    3201  GACTTGAGCG TCGATTTTTG TGATGCTCGT CAGGGGGGCG GAGCCTATGG
    
    3251  AAAAACGCCA GCAACGCGGC CTTTTTACGG TTCCTGGCCT TTTGCTGGCC
    
    3301  TTTTGCTCAC ATGGCTCGAC

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥1000
    上海信裕生物科技有限公司
    2025年07月13日询价
    ¥1000
    上海再康生物科技有限公司
    2025年11月20日询价
    ¥800
    上海沪震实业有限公司
    2025年07月13日询价
    ¥1000
    上海泽叶生物科技有限公司
    2025年07月13日询价
    ¥1200
    上海盖宁生物科技有限公司
    2025年12月01日询价
    pRL-null载体
    ¥800